XERS
Xeris Biopharma Holdings, Inc.
Price Chart
Latest Quote
$8.69
-0.01 (-0.11%)
Current Price
| Previous Close | $8.70 |
| Open | $8.70 |
| Day High | $8.88 |
| Day Low | $8.65 |
| Volume | 1,525,249 |
Stock Information
| Shares Outstanding | 172.64M |
| Total Debt | $258.55M |
| Cash Equivalents | $111.75M |
| Revenue | $314.85M |
| Net Income | $12.01M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.52B |
| P/E Ratio | 125.71 |
| EPS (TTM) | $0.07 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.67B |
| Sales | $314.85M |
| Income | $12.01M |
| Book/sh | $0.08 |
| Cash/sh | $0.65 |
| Employees | 435 |
Financial Ratios
| Quick Ratio | 1.42 |
| Current Ratio | 2.12 |
| Debt/Eq | 1987.19 |
Returns & Margins
| ROA | 6.34% |
| Gross Margin | 85.89% |
| Operating Margin | 9.52% |
| Profit Margin | 3.81% |
Ownership
| Insider Ownership | 3.38% |
| Institutional Ownership | 62.60% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 22.42 |
| P/S | 4.83 |
| P/B | 107.32 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $11.29 |
Technical Indicators
| SMA20 | $8.05 |
| SMA50 | $7.04 |
| SMA200 | $7.07 |
| RSI | 70.63 |
| ATR | 0.3721 |
| Shares Float | 166.28M |
| Short Float | 7.65% |
| Short Ratio | 6.20 |
| Volatility | 0.85 |
| Rel Volume | 0.68 |
Performance History
| Week | +5.52% |
| Month | +27.54% |
| Quarter | +43.79% |
| 6 Months | +16.09% |
| YTD | +19.73% |
| Year | +67.30% |
| 3 Years | +266.67% |
| 5 Years | +121.66% |
| 10 Years | -56.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $8.80 | 1,610,200 |
| 2026-07-16 | $8.69 | 1,572,200 |
| 2026-07-15 | $8.70 | 1,440,200 |
| 2026-07-14 | $8.28 | 1,219,400 |
| 2026-07-13 | $8.16 | 1,471,700 |
| 2026-07-10 | $8.34 | 1,528,200 |
| 2026-07-09 | $8.62 | 2,057,000 |
| 2026-07-08 | $8.67 | 3,676,900 |
| 2026-07-07 | $8.94 | 3,494,200 |
| 2026-07-06 | $8.37 | 1,914,800 |
| 2026-07-02 | $8.28 | 3,748,900 |
| 2026-07-01 | $8.00 | 2,727,500 |
| 2026-06-30 | $7.92 | 2,194,900 |
| 2026-06-29 | $7.74 | 2,575,700 |
| 2026-06-26 | $7.69 | 6,342,500 |
| 2026-06-25 | $7.40 | 1,916,600 |
| 2026-06-24 | $7.40 | 1,741,700 |
| 2026-06-23 | $7.20 | 1,978,900 |
| 2026-06-22 | $6.90 | 1,692,000 |
| 2026-06-18 | $6.95 | 2,398,800 |
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
đ° Latest News
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
Zacks âĸ 2026-07-08T14:37:00Z
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
Insider Monkey âĸ 2026-06-30T13:08:25Z
Jim Cramer Blesses a Callerâs Speculative Investment in Xeris Biopharma
Insider Monkey âĸ 2026-06-12T14:45:19Z
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings
Simply Wall St. âĸ 2026-05-15T11:49:43Z
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit
Simply Wall St. âĸ 2026-05-09T14:19:20Z
Xeris Biopharma Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-09T08:07:05Z
Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Xeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's Changed
Simply Wall St. âĸ 2026-05-08T09:13:12Z
Xeris (XERS) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-07T20:13:55Z
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks âĸ 2026-05-07T13:30:05Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $40,719,000 | $35,050,000 | $26,328,000 | $20,809,000 |
| Cost Of Revenue | $42,569,000 | $36,832,000 | $28,645,000 | $22,634,000 |
| Total Revenue | $291,845,000 | $203,070,000 | $163,914,000 | $110,248,000 |
| Operating Revenue | $291,845,000 | $203,070,000 | $163,914,000 | $110,248,000 |
| Expenses | ||||
| Interest Expense | $29,084,000 | $30,485,000 | $26,609,000 | $14,102,000 |
| Total Expenses | $266,949,000 | $236,716,000 | $207,924,000 | $192,188,000 |
| Net Non Operating Interest Income Expense | $-24,342,000 | $-25,164,000 | $-21,858,000 | $-11,524,000 |
| Interest Expense Non Operating | $29,084,000 | $30,485,000 | $26,609,000 | $14,102,000 |
| Operating Expense | $224,380,000 | $199,884,000 | $179,279,000 | $169,554,000 |
| Other Income Expense | - | $1,706,000 | $2,364,000 | $-2,620,000 |
| Total Other Finance Cost | - | $2,690,000 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $554,000 | $-54,836,000 | $-62,255,000 | $-94,660,000 |
| Net Interest Income | $-24,342,000 | $-25,164,000 | $-21,858,000 | $-11,524,000 |
| Interest Income | $4,742,000 | $5,321,000 | $4,751,000 | $2,578,000 |
| Normalized Income | $554,000 | $-56,474,243 | $-64,572,505 | $-92,078,829 |
| Net Income From Continuing And Discontinued Operation | $554,000 | $-54,836,000 | $-62,255,000 | $-94,660,000 |
| Total Operating Income As Reported | $24,896,000 | $-33,646,000 | $-44,010,000 | $-81,940,000 |
| Net Income Common Stockholders | $554,000 | $-54,836,000 | $-62,255,000 | $-94,660,000 |
| Net Income | $554,000 | $-54,836,000 | $-62,255,000 | $-94,660,000 |
| Net Income Including Noncontrolling Interests | $554,000 | $-54,836,000 | $-62,255,000 | $-94,660,000 |
| Net Income Continuous Operations | $554,000 | $-54,836,000 | $-62,255,000 | $-94,660,000 |
| Pretax Income | $554,000 | $-57,104,000 | $-63,504,000 | $-96,084,000 |
| Special Income Charges | $0 | $1,698,000 | $2,363,000 | $-4,380,000 |
| Interest Income Non Operating | $4,742,000 | $5,321,000 | $4,751,000 | $2,578,000 |
| Operating Income | $24,896,000 | $-33,646,000 | $-44,010,000 | $-81,940,000 |
| Depreciation Amortization Depletion Income Statement | $10,843,000 | $10,843,000 | $10,843,000 | $10,843,000 |
| Depreciation And Amortization In Income Statement | $10,843,000 | $10,843,000 | $10,843,000 | $10,843,000 |
| Amortization Of Intangibles Income Statement | $10,843,000 | $10,843,000 | $10,843,000 | $10,843,000 |
| Gross Profit | $249,276,000 | $166,238,000 | $135,269,000 | $87,614,000 |
| Per Share | ||||
| Diluted EPS | $0.00 | $-0.37 | $-0.45 | $-0.70 |
| Basic EPS | $0.00 | $-0.37 | $-0.45 | $-0.70 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $67,757 | $46,495 | $-38,829 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $42,331,000 | $-15,700,000 | $-26,099,000 | $-66,694,000 |
| Total Unusual Items | $0 | $1,706,000 | $2,364,000 | $-2,620,000 |
| Total Unusual Items Excluding Goodwill | $0 | $1,706,000 | $2,364,000 | $-2,620,000 |
| Reconciled Depreciation | $12,693,000 | $12,625,000 | $13,160,000 | $12,668,000 |
| EBITDA (Bullshit earnings) | $42,331,000 | $-13,994,000 | $-23,735,000 | $-69,314,000 |
| EBIT | $29,638,000 | $-26,619,000 | $-36,895,000 | $-81,982,000 |
| Diluted Average Shares | $172,742,720 | $146,772,758 | $137,674,857 | $135,628,721 |
| Basic Average Shares | $160,425,198 | $146,772,758 | $137,674,857 | $135,628,721 |
| Diluted NI Availto Com Stockholders | $554,000 | $-54,836,000 | $-62,255,000 | $-94,660,000 |
| Tax Provision | $0 | $-2,268,000 | $-1,249,000 | $-1,424,000 |
| Restructuring And Mergern Acquisition | $0 | $-4,388,000 | $-5,200,000 | $3,157,000 |
| Amortization | $10,843,000 | $10,843,000 | $10,843,000 | $10,843,000 |
| Research And Development | $31,165,000 | $25,560,000 | $22,341,000 | $20,966,000 |
| Selling General And Administration | $182,372,000 | $163,481,000 | $146,095,000 | $137,745,000 |
| Other Special Charges | - | $2,690,000 | $2,837,000 | $1,223,000 |
| Gain On Sale Of Security | - | $8,000 | $1,000 | $1,760,000 |
Fetched: 2026-07-01
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-97,248,000 | $-151,395,000 | $-139,405,000 | $-98,279,000 |
| Total Assets | $383,527,000 | $323,060,000 | $322,602,000 | $344,522,000 |
| Total Non Current Assets | $143,214,000 | $155,398,000 | $166,338,000 | $157,704,000 |
| Other Non Current Assets | $5,220,000 | $5,407,000 | $4,540,000 | $4,730,000 |
| Goodwill And Other Intangible Assets | $110,937,000 | $121,780,000 | $132,623,000 | $143,466,000 |
| Other Intangible Assets | $88,078,000 | $98,921,000 | $109,764,000 | $120,607,000 |
| Current Assets | $240,313,000 | $167,662,000 | $156,264,000 | $186,818,000 |
| Other Current Assets | $9,548,000 | $7,451,000 | $5,778,000 | $9,287,000 |
| Inventory | $68,673,000 | $48,175,000 | $38,838,000 | $24,735,000 |
| Receivables | $51,050,000 | $40,415,000 | $39,197,000 | $30,830,000 |
| Accounts Receivable | $51,050,000 | $40,415,000 | $39,197,000 | $30,830,000 |
| Cash Cash Equivalents And Short Term Investments | $111,042,000 | $71,621,000 | $72,451,000 | $121,966,000 |
| Cash And Cash Equivalents | $111,042,000 | $71,621,000 | $67,449,000 | $121,966,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $109,293,000 | $160,487,000 | $123,483,000 | $65,109,000 |
| Total Debt | $258,098,000 | $271,447,000 | $229,191,000 | $198,057,000 |
| Long Term Debt And Capital Lease Obligation | $251,866,000 | $250,265,000 | $225,696,000 | $196,477,000 |
| Long Term Debt | $220,335,000 | $217,006,000 | $190,932,000 | $187,075,000 |
| Current Debt And Capital Lease Obligation | $6,232,000 | $21,182,000 | $3,495,000 | $1,580,000 |
| Current Debt | - | $15,102,000 | - | - |
| Other Current Borrowings | - | $15,102,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $369,838,000 | $352,675,000 | $329,384,000 | $299,335,000 |
| Total Non Current Liabilities Net Minority Interest | $260,264,000 | $252,232,000 | $234,191,000 | $225,714,000 |
| Other Non Current Liabilities | $8,398,000 | $1,967,000 | $6,227,000 | $25,719,000 |
| Current Liabilities | $109,574,000 | $100,443,000 | $95,193,000 | $73,621,000 |
| Other Current Liabilities | $4,889,000 | $1,089,000 | $20,276,000 | $2,658,000 |
| Payables And Accrued Expenses | $55,423,000 | $39,513,000 | $40,268,000 | $44,810,000 |
| Interest Payable | $505,000 | $2,123,000 | $1,374,000 | $4,656,000 |
| Payables | $3,076,000 | $2,290,000 | $11,565,000 | $4,606,000 |
| Accounts Payable | $3,076,000 | $2,290,000 | $11,565,000 | $4,606,000 |
| Non Current Deferred Liabilities | - | $0 | $2,268,000 | $3,518,000 |
| Non Current Deferred Taxes Liabilities | - | $0 | $2,268,000 | $3,518,000 |
| Equity | ||||
| Common Stock Equity | $13,689,000 | $-29,615,000 | $-6,782,000 | $45,187,000 |
| Total Equity Gross Minority Interest | $13,689,000 | $-29,615,000 | $-6,782,000 | $45,187,000 |
| Stockholders Equity | $13,689,000 | $-29,615,000 | $-6,782,000 | $45,187,000 |
| Gains Losses Not Affecting Retained Earnings | $-25,000 | $-25,000 | $-25,000 | $-23,000 |
| Other Equity Adjustments | $-25,000 | $-25,000 | $-25,000 | $-23,000 |
| Retained Earnings | $-671,307,000 | $-671,861,000 | $-617,025,000 | $-554,770,000 |
| Other | ||||
| Ordinary Shares Number | $166,215,410 | $149,429,410 | $138,130,715 | $136,273,090 |
| Share Issued | $166,215,410 | $149,429,410 | $138,130,715 | $136,273,090 |
| Tangible Book Value | $-97,248,000 | $-151,395,000 | $-139,405,000 | $-98,279,000 |
| Invested Capital | $234,024,000 | $202,493,000 | $184,150,000 | $232,262,000 |
| Working Capital | $130,739,000 | $67,219,000 | $61,071,000 | $113,197,000 |
| Capital Lease Obligations | $37,763,000 | $39,339,000 | $38,259,000 | $10,982,000 |
| Total Capitalization | $234,024,000 | $187,391,000 | $184,150,000 | $232,262,000 |
| Additional Paid In Capital | $685,004,000 | $642,256,000 | $610,254,000 | $599,966,000 |
| Capital Stock | $17,000 | $15,000 | $14,000 | $14,000 |
| Common Stock | $17,000 | $15,000 | $14,000 | $14,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $31,531,000 | $33,259,000 | $34,764,000 | $9,402,000 |
| Current Capital Lease Obligation | $6,232,000 | $6,080,000 | $3,495,000 | $1,580,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $24,061,000 | $19,577,000 | $16,956,000 | $13,400,000 |
| Current Provisions | $18,969,000 | $19,082,000 | $14,198,000 | $11,173,000 |
| Current Accrued Expenses | $52,347,000 | $37,223,000 | $28,703,000 | $40,204,000 |
| Goodwill | $22,859,000 | $22,859,000 | $22,859,000 | $22,859,000 |
| Net PPE | $27,057,000 | $28,211,000 | $29,175,000 | $9,508,000 |
| Accumulated Depreciation | $-8,177,000 | $-7,263,000 | $-6,036,000 | $-5,534,000 |
| Gross PPE | $35,234,000 | $35,474,000 | $35,211,000 | $15,042,000 |
| Leases | $5,695,000 | $6,056,000 | $5,984,000 | $5,065,000 |
| Other Properties | $5,325,000 | $4,730,000 | $4,153,000 | $3,841,000 |
| Machinery Furniture Equipment | $2,102,000 | $2,039,000 | $1,870,000 | $2,144,000 |
| Buildings And Improvements | $22,112,000 | $22,649,000 | $23,204,000 | $3,992,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $19,368,000 | $5,452,000 | $10,475,000 | $5,958,000 |
| Work In Process | $11,295,000 | $10,991,000 | $10,959,000 | $11,367,000 |
| Raw Materials | $38,010,000 | $31,732,000 | $17,404,000 | $7,410,000 |
| Other Short Term Investments | - | $0 | $5,002,000 | $0 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-07-01
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $27,930,000 | $-37,849,000 | $-49,286,000 | $-103,415,000 |
| Operating Activities | ||||
| Operating Cash Flow | $28,626,000 | $-36,981,000 | $-47,023,000 | $-102,891,000 |
| Cash Flow From Continuing Operating Activities | $28,626,000 | $-36,981,000 | $-47,023,000 | $-102,891,000 |
| Operating Gains Losses | - | $83,000 | $2,837,000 | $-301,000 |
| Investing Activities | ||||
| Capital Expenditure | $-696,000 | $-868,000 | $-2,263,000 | $-524,000 |
| Investing Cash Flow | $-696,000 | $4,883,000 | $-6,004,000 | $34,461,000 |
| Cash Flow From Continuing Investing Activities | $-696,000 | $4,883,000 | $-6,004,000 | $34,461,000 |
| Capital Expenditure Reported | $-696,000 | $-868,000 | $-2,263,000 | $-524,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-10,876,000 | $-3,734,000 | $-1,009,000 | $-468,000 |
| Issuance Of Capital Stock | $9,167,000 | $0 | $0 | $30,000,000 |
| Financing Cash Flow | $11,389,000 | $36,168,000 | $-1,613,000 | $127,473,000 |
| Cash Flow From Continuing Financing Activities | $11,389,000 | $36,168,000 | $-1,613,000 | $127,473,000 |
| Net Common Stock Issuance | $-1,709,000 | $-3,734,000 | $-1,009,000 | $29,532,000 |
| Common Stock Issuance | $9,167,000 | $0 | $0 | $30,000,000 |
| Net Other Financing Charges | - | - | $-1,185,000 | $-4,876,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-11,831,000 | $0 | $-44,233,000 |
| Issuance Of Debt | $0 | $50,000,000 | $0 | $146,214,000 |
| Interest Paid Supplemental Data | $27,120,000 | $26,948,000 | $27,686,000 | $10,859,000 |
| End Cash Position | $115,063,000 | $75,744,000 | $71,674,000 | $126,314,000 |
| Beginning Cash Position | $75,744,000 | $71,674,000 | $126,314,000 | $67,271,000 |
| Changes In Cash | $39,319,000 | $4,070,000 | $-54,640,000 | $59,043,000 |
| Proceeds From Stock Option Exercised | $13,098,000 | $1,733,000 | $581,000 | $836,000 |
| Common Stock Payments | $-10,876,000 | $-3,734,000 | $-1,009,000 | $-468,000 |
| Net Issuance Payments Of Debt | $0 | $38,169,000 | $0 | $101,981,000 |
| Net Long Term Debt Issuance | $0 | $38,169,000 | $0 | $101,981,000 |
| Long Term Debt Payments | $0 | $-11,831,000 | $0 | $-44,233,000 |
| Long Term Debt Issuance | $0 | $50,000,000 | $0 | $146,214,000 |
| Net Investment Purchase And Sale | $0 | $5,751,000 | $-3,741,000 | $34,985,000 |
| Sale Of Investment | $0 | $40,236,000 | $40,000,000 | $34,985,000 |
| Purchase Of Investment | $0 | $-34,485,000 | $-43,741,000 | $0 |
| Change In Working Capital | $-10,360,000 | $-8,820,000 | $-6,294,000 | $-35,150,000 |
| Change In Other Working Capital | $3,610,000 | $3,812,000 | $6,418,000 | $9,680,000 |
| Change In Other Current Liabilities | $-1,576,000 | $1,080,000 | $818,000 | $-6,179,000 |
| Change In Payables And Accrued Expense | $19,624,000 | $-2,039,000 | $6,435,000 | $-13,925,000 |
| Change In Accrued Expense | $19,693,000 | $7,574,000 | $-524,000 | $-9,607,000 |
| Change In Payable | $-69,000 | $-9,613,000 | $6,959,000 | $-4,318,000 |
| Change In Account Payable | $-69,000 | $-9,613,000 | $6,959,000 | $-4,318,000 |
| Change In Prepaid Assets | $-2,097,000 | $-1,673,000 | $3,206,000 | $-3,887,000 |
| Change In Inventory | $-19,286,000 | $-8,782,000 | $-14,804,000 | $-7,465,000 |
| Change In Receivables | $-10,635,000 | $-1,218,000 | $-8,367,000 | $-13,374,000 |
| Changes In Account Receivables | $-10,635,000 | $-1,218,000 | $-8,367,000 | $-13,374,000 |
| Other Non Cash Items | $3,373,000 | $-1,298,000 | $-2,675,000 | $3,632,000 |
| Stock Based Compensation | $22,366,000 | $18,363,000 | $10,716,000 | $12,160,000 |
| Amortization Of Securities | $0 | $-747,000 | $-1,263,000 | $184,000 |
| Deferred Tax | $0 | $-2,268,000 | $-1,249,000 | $-1,424,000 |
| Deferred Income Tax | $0 | $-2,268,000 | $-1,249,000 | $-1,424,000 |
| Depreciation Amortization Depletion | $12,693,000 | $12,625,000 | $13,160,000 | $12,668,000 |
| Depreciation And Amortization | $12,693,000 | $12,625,000 | $13,160,000 | $12,668,000 |
| Amortization Cash Flow | $10,843,000 | $10,843,000 | $10,843,000 | $10,843,000 |
| Amortization Of Intangibles | $10,843,000 | $10,843,000 | $10,843,000 | $10,843,000 |
| Depreciation | $1,850,000 | $1,782,000 | $2,317,000 | $1,825,000 |
| Net Income From Continuing Operations | $554,000 | $-54,836,000 | $-62,255,000 | $-94,660,000 |
| Gain Loss On Investment Securities | - | $-8,000 | $-1,000 | $-1,760,000 |
| Gain Loss On Sale Of PPE | - | $91,000 | $321,000 | $236,000 |
| Effect Of Exchange Rate Changes | - | - | $0 | $0 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Sale Of Business | - | - | $0 | $0 |
Fetched: 2026-07-01